Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Japan.
Ann Nucl Med. 2011 May;25(4):247-53. doi: 10.1007/s12149-010-0455-x. Epub 2010 Dec 21.
Positron emission tomography (PET) with fluorine-18-fluorodeoxyglucose ((18)F-FDG) has been studied in thymic epithelial tumors. We evaluated the usefulness of (18)F-FDG PET for monitoring after treatment in unresectable thymic epithelial tumors.
Twelve patients with unresectable/metastatic thymic epithelial tumors underwent PET study with (18)F-FDG before and after chemotherapy or radiotherapy. Response and survival were analyzed according to the ratio of the peak standardized uptake value (SUV) of the tumor to the mean SUV of the mediastinum (T/M ratio).
Partial response (PR) evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) was noted in 4 (33%) of 12 patients, and partial metabolic response (PMR) was observed in 6 (50%) of 12 patients. PR was observed in 4 of 6 patients with PMR. In 6 patients with any response, the T/M ratio at post-treatment was significantly lower than at baseline (p = 0.0017). In 6 patients with stable disease (SD), stable metabolic disease (SMD) was observed in 5 by use of (18)F-FDG PET. No statistically significant difference of (18)F-FDG uptake between at baseline and post-therapy was observed in 6 patients with SD (p = 0.4157) and SMD (p = 0.8419). Although the overall survival after treatment showed no statistically significant difference between PMR and SMD or progressive metabolic disease in the whole group of patients including thymoma, a statistically significant difference in the overall survival was observed between 5 patients with PMR and 5 patients with non-PMR (p = 0.0280).
Our preliminary study suggests that (18)F-FDG PET is useful for monitoring response and outcome after treatment in unresectable thymic epithelial tumors.
正电子发射断层扫描（PET）结合氟-18-氟代脱氧葡萄糖（(18)F-FDG）已在胸腺瘤中进行了研究。我们评估了（18）F-FDG PET 在监测不可切除胸腺癌治疗后的有效性。
12 例不可切除/转移性胸腺癌患者在化疗或放疗前后接受（18）F-FDG PET 检查。根据肿瘤峰值标准化摄取值（SUV）与纵隔平均 SUV 的比值（T/M 比值）分析反应和生存情况。
根据实体瘤反应评价标准（RECIST），4 例（33%）患者评估为部分缓解（PR），12 例患者中有 6 例（50%）观察到部分代谢缓解（PMR）。在 6 例有任何反应的患者中，治疗后 T/M 比值明显低于基线（p = 0.0017）。在 6 例疾病稳定（SD）的患者中，5 例使用（18）F-FDG PET 观察到稳定代谢疾病（SMD）。在 6 例 SD 患者中，（18）F-FDG 摄取在基线与治疗后之间无统计学差异（p = 0.4157），在 6 例 SMD 患者中也无统计学差异（p = 0.8419）。尽管在包括胸腺瘤在内的所有患者中，PMR 与 SMD 或进行性代谢疾病之间的总生存期无统计学差异，但在 5 例 PMR 患者与 5 例非 PMR 患者之间，总生存期有统计学差异（p = 0.0280）。
我们的初步研究表明，（18）F-FDG PET 可用于监测不可切除胸腺癌治疗后的反应和结果。
